NCT00139919View on ClinicalTrials.gov

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

January 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

SchizophreniaSchizoaffective DisorderBipolar Disorder

Interventions

DRUG

Bifeprunox

Trial Locations (1)

Unknown

Site 1, Orange

All Listed Sponsors

collaborator

H. Lundbeck A/S

INDUSTRY

collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Solvay Pharmaceuticals

INDUSTRY

NCT00139919 - Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder | Biotech Hunter | Biotech Hunter